Management of hypertension in high-risk ethnic minority with heart failure

M. Demede, A. Pandey, L. Innasimuthu, G. Jean-Louis, S. I. McFarlane, G. Ogedegbe

Research output: Contribution to journalArticle

Abstract

Hypertension (HTN) is the most common co-morbidity in the world, and its sequelae, heart failure (HF) is one of most common causes of mortality and morbidity in the world. Current understanding of pathophysiology and management of HTN in HF is mainly based on studies, which have mainly included whites. Among racial groups, African-American adults have the highest rates (44) of hypertension in the world and are more resistant to treatment. There is an emerging consensus on the significance of racial disparities in the pathophysiology and treatment options of hypertension and heart failure. However, African Americans had been underrepresented in all the trials until the initiation of the A-HEFT trial. Since the recognition of obstructive sleep apnea (OSA) as an important medical condition, large clinical trials have shown benefits of OSA treatment among patients with HTN and HF. This paper focuses on the pathophysiology, causes of secondary hypertension, and treatment of hypertension among African-American patients with heart failure. There is increasing need for randomized clinical trials testing innovative treatment options for African-American patients.

Original languageEnglish (US)
Article number417594
JournalInternational Journal of Hypertension
Volume2011
DOIs
StatePublished - 2011

Fingerprint

Heart Failure
Hypertension
African Americans
Obstructive Sleep Apnea
Morbidity
Therapeutics
Randomized Controlled Trials
Clinical Trials
Mortality

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Management of hypertension in high-risk ethnic minority with heart failure. / Demede, M.; Pandey, A.; Innasimuthu, L.; Jean-Louis, G.; McFarlane, S. I.; Ogedegbe, G.

In: International Journal of Hypertension, Vol. 2011, 417594, 2011.

Research output: Contribution to journalArticle

Demede, M. ; Pandey, A. ; Innasimuthu, L. ; Jean-Louis, G. ; McFarlane, S. I. ; Ogedegbe, G. / Management of hypertension in high-risk ethnic minority with heart failure. In: International Journal of Hypertension. 2011 ; Vol. 2011.
@article{890585d1ab4e450d9b57df9201c7d1a6,
title = "Management of hypertension in high-risk ethnic minority with heart failure",
abstract = "Hypertension (HTN) is the most common co-morbidity in the world, and its sequelae, heart failure (HF) is one of most common causes of mortality and morbidity in the world. Current understanding of pathophysiology and management of HTN in HF is mainly based on studies, which have mainly included whites. Among racial groups, African-American adults have the highest rates (44) of hypertension in the world and are more resistant to treatment. There is an emerging consensus on the significance of racial disparities in the pathophysiology and treatment options of hypertension and heart failure. However, African Americans had been underrepresented in all the trials until the initiation of the A-HEFT trial. Since the recognition of obstructive sleep apnea (OSA) as an important medical condition, large clinical trials have shown benefits of OSA treatment among patients with HTN and HF. This paper focuses on the pathophysiology, causes of secondary hypertension, and treatment of hypertension among African-American patients with heart failure. There is increasing need for randomized clinical trials testing innovative treatment options for African-American patients.",
author = "M. Demede and A. Pandey and L. Innasimuthu and G. Jean-Louis and McFarlane, {S. I.} and G. Ogedegbe",
year = "2011",
doi = "10.4061/2011/417594",
language = "English (US)",
volume = "2011",
journal = "International Journal of Hypertension",
issn = "2090-0384",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Management of hypertension in high-risk ethnic minority with heart failure

AU - Demede, M.

AU - Pandey, A.

AU - Innasimuthu, L.

AU - Jean-Louis, G.

AU - McFarlane, S. I.

AU - Ogedegbe, G.

PY - 2011

Y1 - 2011

N2 - Hypertension (HTN) is the most common co-morbidity in the world, and its sequelae, heart failure (HF) is one of most common causes of mortality and morbidity in the world. Current understanding of pathophysiology and management of HTN in HF is mainly based on studies, which have mainly included whites. Among racial groups, African-American adults have the highest rates (44) of hypertension in the world and are more resistant to treatment. There is an emerging consensus on the significance of racial disparities in the pathophysiology and treatment options of hypertension and heart failure. However, African Americans had been underrepresented in all the trials until the initiation of the A-HEFT trial. Since the recognition of obstructive sleep apnea (OSA) as an important medical condition, large clinical trials have shown benefits of OSA treatment among patients with HTN and HF. This paper focuses on the pathophysiology, causes of secondary hypertension, and treatment of hypertension among African-American patients with heart failure. There is increasing need for randomized clinical trials testing innovative treatment options for African-American patients.

AB - Hypertension (HTN) is the most common co-morbidity in the world, and its sequelae, heart failure (HF) is one of most common causes of mortality and morbidity in the world. Current understanding of pathophysiology and management of HTN in HF is mainly based on studies, which have mainly included whites. Among racial groups, African-American adults have the highest rates (44) of hypertension in the world and are more resistant to treatment. There is an emerging consensus on the significance of racial disparities in the pathophysiology and treatment options of hypertension and heart failure. However, African Americans had been underrepresented in all the trials until the initiation of the A-HEFT trial. Since the recognition of obstructive sleep apnea (OSA) as an important medical condition, large clinical trials have shown benefits of OSA treatment among patients with HTN and HF. This paper focuses on the pathophysiology, causes of secondary hypertension, and treatment of hypertension among African-American patients with heart failure. There is increasing need for randomized clinical trials testing innovative treatment options for African-American patients.

UR - http://www.scopus.com/inward/record.url?scp=84868295232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868295232&partnerID=8YFLogxK

U2 - 10.4061/2011/417594

DO - 10.4061/2011/417594

M3 - Article

C2 - 21747977

AN - SCOPUS:84868295232

VL - 2011

JO - International Journal of Hypertension

JF - International Journal of Hypertension

SN - 2090-0384

M1 - 417594

ER -